Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group-Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future.
Krishna R, Sebastien B, Corriol-Rohou S, Cheung SYA, Liu J, Suryawanshi S. Krishna R, et al. Among authors: sebastien b. Clin Pharmacol Ther. 2024 Dec;116(6):1433-1441. doi: 10.1002/cpt.3422. Epub 2024 Aug 15. Clin Pharmacol Ther. 2024. PMID: 39145605 Review.
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.
Cortés J, Hurvitz SA, O'Shaughnessy J, Delaloge S, Iwata H, Rugo HS, Neven P, Kanagavel D, Cohen P, Paux G, Cartot-Cotton S, Stefanova-Urena M, Deyme L, Aouni J, Sebastien B, Bardia A. Cortés J, et al. Among authors: sebastien b. J Clin Oncol. 2024 Aug 1;42(22):2680-2690. doi: 10.1200/JCO.23.02036. Epub 2024 Jun 18. J Clin Oncol. 2024. PMID: 38889373 Clinical Trial.
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Rachedi F, Koiwai K, Gaudel-Dedieu N, Sebastien B, Thai HT, Brillac C, Fau JB, Nguyen L, van de Velde H, Veyrat-Follet C, Semiond D. Rachedi F, et al. Among authors: sebastien b. CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):766-777. doi: 10.1002/psp4.12789. Epub 2022 Apr 17. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35355430 Free PMC article. Clinical Trial.
26 results